Stem, Inc. Announces Reverse Stock Split and Authorized Shares Reduction

Stem, Inc. (NYSE: STEM), currently trading at $0.47 with a $77M market cap after a 59% stock decline in the past year, announced a 1-for-20 reverse stock split effective June 23, 2025, and a reduction of authorized shares from 500M to 250M, alongside reporting Q1 2025 revenue of $32.5M (vs. $31.27M est.) and EPS of -$0.15 (vs. -$0.19 est.). The move aims to address financial challenges, including a $593.58M debt burden and negative EBITDA of -$82.67M, and regain NYSE compliance, despite recent positive operating cash flow of $9M and a 27% workforce reduction for $30M in cost savings.

Analysis

Stem, Inc. is undertaking a 1-for-20 reverse stock split effective June 23, 2025, and reducing authorized common shares from 500 million to 250 million, principally to address NYSE minimum price compliance after its stock, currently $0.47, fell 59% in the past year. This action occurs amidst severe financial challenges, including a significant $593.58 million debt burden, negative EBITDA of -$82.67 million (LTM), a weak InvestingPro financial health score of 1.31, and 14 identified key risk factors. Despite these pressures, Stem's Q1 2025 earnings showed some positive signals: revenue reached $32.5 million, surpassing the $31.27 million forecast, and EPS was -$0.15, better than the anticipated -$0.19. The company also reported a 27% year-over-year revenue increase, its first positive operating cash flow of $9 million, and initiated a 27% workforce reduction aiming for $30 million in annual cost savings. These measures reflect a critical attempt to stabilize the company, though substantial underlying financial risks persist, underscored by a cautious market sentiment with a per-ticker sentiment score of -0.3 for STEM.

Key Decisions for Investors

• Investors should recognize Stem's 1-for-20 reverse stock split primarily as a measure to maintain NYSE listing compliance, not as an indicator of fundamental improvement, especially given its substantial $593.58 million debt burden and negative EBITDA.
• Carefully weigh the recent Q1 2025 positive operational developments, such as surpassing revenue expectations at $32.5 million, achieving $9 million in positive operating cash flow, and a $30 million cost-saving plan, against the company's weak financial health score of 1.31 and 14 identified key risk factors.
• Monitor the company's ability to sustain positive cash flow and realize targeted cost savings as critical milestones for any potential turnaround, approaching any investment with significant caution due to the highly speculative nature of the stock and its financial leverage.